Trabedersen AP 12009|cas:925681-61-4|西域试剂

Trabedersen AP 12009

产品编号：Bellancom-142118| CAS NO：925681-61-4| 分子量：5768.70

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	包装	价格	库存与货期	购买量	操作
Bellancom-142118		￥4700.00	杭州北京（现货）
Bellancom-142118		￥10500.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

Trabedersen AP 12009

产品介绍

Trabedersen (AP 12009) 是一种反义寡脱氧核苷酸，可特异性抑制 TGF-β2 (TGF-beta/Smad)。Trabedersen 可用于研究恶性脑肿瘤和其他过度表达 TGF-β2 的实体瘤，例如皮肤、胰腺和结肠肿瘤。

生物活性

Trabedersen (AP 12009) is an antisense oligodeoxynucleotide that specifically inhibits TGF-β2 (TGF-beta/Smad). Trabedersen can be used for the study of malignant brain tumors and other solid tumors overexpressing TGF-β2, such as those of the skin, pancreas and colon.

体外研究

Trabedersen (1-80 μM; 7 days) reduces TGF-β2 secretion in human pancreatic cancer cell line Hup-T3 with an IC₅₀ in the low μM range, clearly inhibits cell proliferation, and completely blocks migration of pancreatic cancer cells.
Trabedersen reverses TGF-β2-mediated immunosuppression of pancreatic cancer cells.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay

Cell Line:	Hup-T3 cells
Concentration:	1 μM, 2.5 μM, 5 μM, 10 μM, 20 μM, 40 μM, 60 μM, 80 μM
Incubation Time:	7 days
Result:	Inhibited cell proliferation, and completely blocked migration of pancreatic cancer cells.

体内研究
(In Vivo)

Trabedersen (initial loading dose of 50 mg/kg bodyweight followed by 16 mg/kg three times a week; i.p.) treatment significantly reduces tumor growth, lymph node metastasis and angiogenesis in an orthotopic mouse model of metastatic pancreatic cancer.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Eight-week-old male athymic nude mice (BALB⁄Cnu ⁄nu) bearing human pancreatic cancer cells.
Dosage:	Initial loading dose of 50 mg/kg bodyweight followed by 16 mg/kg three times a week.
Administration:	Intraperitoneal (i.p.) injection; three times a week; for 27 days
Result:	Significantly reduced tumor growth, lymph node metastasis and angiogenesis.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Eight-week-old male athymic nude mice (BALB⁄Cnu ⁄nu) bearing human pancreatic cancer cells.
Dosage:	Initial loading dose of 50 mg/kg bodyweight followed by 16 mg/kg three times a week.
Administration:	Intraperitoneal (i.p.) injection; three times a week; for 27 days
Result:	Significantly reduced tumor growth, lymph node metastasis and angiogenesis.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Eight-week-old male athymic nude mice (BALB⁄Cnu ⁄nu) bearing human pancreatic cancer cells.
Dosage:	Initial loading dose of 50 mg/kg bodyweight followed by 16 mg/kg three times a week.
Administration:	Intraperitoneal (i.p.) injection; three times a week; for 27 days
Result:	Significantly reduced tumor growth, lymph node metastasis and angiogenesis.